GoodRx Inc. (GDRX)
NASDAQ: GDRX
· Real-Time Price · USD
4.35
-0.01 (-0.23%)
At close: Aug 29, 2025, 3:59 PM
4.33
-0.46%
Pre-market: Sep 02, 2025, 04:22 AM EDT
-0.23% (1D)
| Bid | 4.38 |
| Market Cap | 1.51B |
| Revenue (ttm) | 799.87M |
| Net Income (ttm) | 42.89M |
| EPS (ttm) | 0.09 |
| PE Ratio (ttm) | 48.33 |
| Forward PE | 9.67 |
| Analyst | Hold |
| Ask | 4.46 |
| Volume | 1,581,661 |
| Avg. Volume (20D) | 2,888,841 |
| Open | 4.33 |
| Previous Close | 4.36 |
| Day's Range | 4.26 - 4.37 |
| 52-Week Range | 3.31 - 8.16 |
| Beta | 1.24 |
About GDRX
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol GDRX
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for GDRX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNext Earnings Release
GoodRx Inc. is scheduled to release its earnings on
Nov 6, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
2 weeks ago
+37.27%
GoodRx shares are trading higher after the company...
Unlock content with
Pro Subscription
3 weeks ago
-20.05%
GoodRx Holdings shares are trading lower after the company reported worse-than-expected Q2 financial results.
2 weeks ago · seekingalpha.com
GoodRx: After A 30% Surge On The Novo News, Is The Story Just Beginning?GoodRx Holdings, Inc.'s partnership with Novo Nordisk highlights its vital role in direct-to-consumer drug pricing, driving a 30% stock surge and validating its business model. Pharma Manufacturer Sol...
2 weeks ago · proactiveinvestors.com
Novo Nordisk expands access to Ozempic, Wegovy through GoodRx and other platformsNovo Nordisk (NYSE:NVO) shares moved higher on Monday after it was announced that US patients can access its diabetes drug Ozempic at a cheaper price through several platforms, expanding access to the...
